3Kober L,Trop-Pedersen C,McMurray JJ.Increased mortality after dronedarone therapy for severe heart failure.N Engl J Med,2008,358:2678-2687.
4Connolly S J,Camm A J,Halperin JL.Dronedarone in high-risk permanent atrial fibrillation.N Engl J Med,2011,365:2268-2276.
5Antzelevitch C,Burashnikov A,Sicouri S.Electrophysiologic basis for the antiarrhythmic of ranolazine.Heart Rhythm,2011,8:1281-1290.
6Burashnikov A,Antzelevitch C.New developments in atrial antiarrhymic drug therapy.Nat Rev Cardiol,2010,7:139-148.
7Cheng JWM,Rybak I.Pharmacotherapy options in atrial Fibrillation:Focus on Vernakalant.Clin Med:Therapeutics,2009,1:215-230.
8Camm AJ,Lip GY,De Caterina R.2012 focused update of ESC guidelines for the management of atrial fibrillation.Europace,2012,14:1385-1413.
9Swedberg K,Komajda M,Bohm M.Ivabradine and outcomes in chronic heart failure (SHIFT):A randomised placebo-controlled study.Lancet,2010,376:875-885.
10McMurray JJ,Adamopoulos S,Anker SD.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012:The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology.Developed in collaboration with the heart failure association (HFA) of the ESC.European J Heart Failure,2012,14:803-869.
5Ahmed LA, Salem HA, Attia AS, et al. Pharmacological precondition-ing with nicorandil and pioglitazone attenuates myocardial ischemia / reperfusion injury in rats[ J]. Eur J Pharmaco1,2011,663 (1/3) :51- 58.
6Yang M J, Lee HC, Lee HW. Effect of nicorandil on clinical outcomes in patients with ST-segment elevation and non-ST-segment elevation myocardial infarction:Based on the Korea Acute Myocardial Infarc- tion Regislry [ J ]. Int J Cardio1,2013,27 (5) :665-667.
